1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ et al. (eds). SEER Cancer Statistics Review 1975–2005. National Cancer Institute: Bethesda, MD. http://seer.cancer.gov/csr/1975_2005/ . based on November 2007 SEER data submission, posted to the SEER website, 2008.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.
3. Cancer Research UK. CancerStats Key Facts on Prostate Cancer. Available from: http://info.cancerresearchuk.org/cancerstats/types/prostate/ . (last accessed 23 September 2009).
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Kim KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512.
5. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–1520.